Most pharma and MedTech teams have invested in omnichannel. They have the channels. What they often do not have is a single story running through all of them.
That distinction cost real brand performance. At Novartis, I built a global marketing operation spanning Neuroscience, Oncology, Cardio-Renal-Metabolic, and Immunology. The brands were different. The customers were different. HCPs, patients, payers, KOLs across the Americas, Europe, and Asia. What could not be different was the core commercial story. I standardized key messages across digital, in-person, and congress touchpoints. I embedded those messages into field team conversations using the same customer narrative. I measured impact through changes in beliefs and prescribing behavior, not clicks or opens.
The Unified Model in Practice
The result was a marketing operation where a physician heard the same story from an email, a rep, and a conference interaction, in the right sequence, at the right moment. That is not omnichannel. That is a unified selling model with channels as the delivery mechanism.
What AI Changes
AI made it faster and sharper. I embedded AI into 50% of those marketing operations across more than 10 brands. The work included message pressure testing against simulated customer segments and real-time creative evaluation. That 20% reduction in operating costs was not the headline. The headline was that AI let us test whether the story was actually landing before the rep walked in the door.
The channel mix is table stakes. The commercial story is the asset.
If you are preparing a brand for launch or rebuilding after one that underperformed, I can show you what a unified selling model looks like in practice. See how I work with pharma and MedTech teams →